Platelet-activating factor in liver injury: A relational scope

World Journal of Gastroenterology

Volumn 12, Issue 23, 2006, Pages 3695-3706

  Karidis, Nikolaos P ^a   Kouraklis, Gregory ^a   Theocharis, Stamatios E ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Injury; Liver; PAF; PAF R antagonists; Regeneration

Indexed keywords

1 ETHYL 2 [N (2 METHOXYBENZOYL) N [2 METHOXY 3 [4 (OCTADECYLCARBAMOYLOXY)PIPERIDINOCARBONYLOXY]PROPOXYCARBONYL]AMINOMETHYL]PYRIDINIUM CHLORIDE; 1 [2 [[5 (N OCTADECYLCARBAMOYLOXYMETHYL)TETRAHYDROFURFURYLOXY]HYDROXYPHOSPHINYLOXY]ETHYL]QUINOLINIUM; 2 [N (2 METHOXY 3 OCTADECYLCARBAMOYLOXYPROPOXYCARBONYL)ACETAMIDOMETHYL] 1 ETHYLPYRIDINIUM CHLORIDE; 3 BROMO 5 [N PHENYL N [2 [[2 (1,2,3,4 TETRAHYDRO 2 ISOQUINOLYLCARBONYLOXY)ETHYL]CARBAMOYL]ETHYL]CARBAMOYL] 1 PROPYLPYRIDINIUM NITRATE; ALANINE AMINOTRANSFERASE; BEPAFANT; GINKGOLIDE B; GLUTAMATE DEHYDROGENASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1; INTERLEUKIN 6; INTERLEUKIN 8; LEXIPAFANT; MYELOPEROXIDASE; PROSTACYCLIN DERIVATIVE; PROSTAGLANDIN D2; PROSTAGLANDIN E2; PURINE NUCLEOSIDE PHOSPHORYLASE; THROMBOCYTE ACTIVATING FACTOR; THROMBOCYTE ACTIVATING FACTOR ANTAGONIST; THROMBOXANE A2 DERIVATIVE; THROMBOXANE B2; TUMOR NECROSIS FACTOR ALPHA;

CALCIUM HOMEOSTASIS; CALCIUM TRANSPORT; CELL DEATH; CELL REGENERATION; CYTOKINE PRODUCTION; DISEASE PREDISPOSITION; DRUG EFFICACY; DRUG PROTEIN BINDING; ENZYME ACTIVATION; HUMAN; LIVER CELL; LIVER INJURY; LIVER ISCHEMIA; LIVER METABOLISM; LIVER PROTECTION; LIVER RESECTION; LIVER TRANSPLANTATION; MOLECULAR INTERACTION; NEUTROPHIL; NONHUMAN; PATHOPHYSIOLOGY; POSTOPERATIVE PERIOD; REPERFUSION INJURY; REVIEW; SURVIVAL RATE; TREATMENT OUTCOME; VASCULAR RESISTANCE;

EID: 33745455904     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v12.i23.3695     Document Type: Review

References (88)

1. Demopoulos CA, Pinckard RN, Hanahan DJ. Platelet-activating factor. Evidence for 1-O-alkyl-2-acetyl-sn-glyceryl-3-phosphorylcholine as the active component (a new class of lipid chemical mediators). J Biol Chem 1979; 254: 9355-9358
2. Pinckard RN, McManus LM, Demopoulos CA, Halonen M, Clark PO, Shaw JO, Kniker WT, Hanahan DJ. Molecular pathobiology of acetyl glyceryl ether phosphorylcholine: evidence for the structural and functional identity with platelet-activating factor. J Reticuloendothel Soc 1980; 28: 95s-103s
3. Stewart AG. Biological properties of platelet activating factor. In: Cunningham FM, ed. Lipid Mediators. London: Academic Press, 1994: 181-192
4. Ishii S, Nagase T, Shimizu T. Platelet-activating factor receptor. Prostaglandins Other Lipid Mediat 2002; 68-69: 599-609
5. Chao W, Olson MS. Platelet-activating factor: receptors and signal transduction. Biochem J 1993; 292 (Pt 3): 617-629
6. Bratton D, Clay K, Henson P. Cellular sources of platelet-activating factor and related lipids. In: Cunningham FM, ed. Lipid Mediators. San Diego: Academic Press, 1994:193-219
7. Snyder F. Biosynthesis and catabolism of platelet activating factor. In: Cunningham FM, ed. The Handbook of Immunopharmacology. New York: Academic Press, 1994:181-192
8. Stafforini DM, Tjoelker LW. Human plasma platelet-activating factor acetylhydrolase. Methods Mol Biol 1999; 109:49-58
9. Tjoelker LW, Stafforini DM. Platelet-activating factor acetyl-hydrolases in health and disease. Biochim Biophys Acta 2000; 1488:102-123
10. Jaeschke H. Molecular mechanisms of hepatic ischemia-reperfusion injury and preconditioning. Am J Physiol Gastrointest Liver Physiol 2003; 284: G15-26
11. Kerrigan CL, Stotland MA. Ischemia reperfusion injury: a review. Microsurgery 1993; 14: 165-175
12. Farber JL. Calcium ions and ischemic liver cell injury. In: Heilmann C, ed. Calcium-dependent processes in the liver. Lancaster, England: MTP Press Limited, 1988: 213
13. Mansbach CM 2nd. Phospholipases: old enzymes with new meaning. Gastroenterology 1990; 98: 1369-1382
14. Welbourn CR, Goldman G, Paterson IS, Valeri CR, Shepro D, Hechtman HB. Pathophysiology of ischaemia reperfusion injury: central role of the neutrophil. Br J Surg 1991; 78: 651-655
15. Albelda SM, Buck CA. Integrins and other cell adhesion molecules. FASEB J 1990; 4: 2868-2880
16. Ruoslahti E. Integrins. J Clin Invest 1991; 87:1-5
17. Toledo-Pereyra LH, Suzuki S. Cellular and biomolecular mechanisms of liver ischemia and reperfusion injury. Transplant Proc 1994; 26: 325-327
18. Ontell SJ, Makowka L, Ove P, Starzl TE. Improved hepatic function in the 24-hour preserved rat liver with UW-lactobionate solution and SRI 63-441. Gastroenterology 1988; 95: 1617-1624
19. Wang KS, Monden M, Kanai T, Umeshita K, Ukei T, Nakano H, Gotoh M, Mori T. Protective effects of a PAF antagonist against liver injury induced by warm ischemia or cold preservation. Transplant Proc 1992; 24: 1596-1598
20. Ontell SJ, Makowka L, Trager J, Mazzaferro V, Ove P, Starzl TE. Pharmacologic modulation of experimental postischemic hepatic function. Ann Surg 1989; 209: 200-210
21. Wang KS, Monden M. Ex vivo evidence of platelet activating factor on ischemic liver injury. Changgeng Yixue Zazhi 1996; 19: 229-234
22. Hashikura Y, Kawasaki S, Matsunami H, Ikegami T, Nakazawa Y, Makuuchi M. Effect of platelet-activating factor on coldpreserved liver grafts. Br J Surg 1994; 81: 1779-1782
23. Wang KS, Monden M, Kanai T, Gotoh M, Umeshita K, Ukei T, Mori T. Protective effect of platelet-activating factor antagonist on ischemia-induced liver injury in rats. Surgery 1993; 113: 76-83
24. Zhou W, McCollum MO, Levine BA, Olson MS. Inflammation and platelet-activating factor production during hepatic ischemia/ reperfusion. Hepatology 1992; 16:1236-1240
25. Zhou WG, Chao W, Levine BA, Olson MS. Evidence for platelet-activating factor as a late-phase mediator of chronic pancreatitis in the rat. Am J Pathol 1990; 137:1501-1508
26. Borobia FG, Figueras J, Escriba JM, Farran L, Rafecas A, Fabregat J, Torras J, Jaurrieta E. Platelet-activating factor antagonist BN52021 improves survival in normothermic liver ischemia in rats. Transplant Proc 1993; 25: 2543-2544
27. Minor T, Isselhard W. Platelet-activating factor antagonism enhances the liver's recovery from warm ischemia in situ. J Hepatol 1993; 18: 365-368
28. Chavez-Cartaya RE, Metcalfe S, Ramirez-Romero P, Calne R, Jamieson NV. Rat liver blood flow after ischemia and reperfusion. The effects of the platelet-activating factor antagonist WEB-2170 and of removing circulating leukocytes. Transplantation 1994; 57:1440-1444
29. Minor T, Isselhard W, Yamaguchi T. Involvement of platelet activating factor in microcirculatory disturbances after global hepatic ischemia. J Surg Res 1995; 58: 536-540
30. Ruan Z, Shibamoto T, Shimo T, Koizumi T, Tsuchida H, Kurata Y, Ogura T, Kubo K. Effects of platelet-activating factor and thromboxane A2 on isolated perfused guinea pig liver. Prostaglandins Other Lipid Mediat 2004; 73: 73-85
31. Nakatani T, Sakamoto Y, Ando H, Kobayashi K. Effects of platelet-activating factor antagonist E5880 on intrahepatic and systemic metabolic responses to transient hepatic inflow occlusion and reperfusion in the rabbit. World J Surg 1996; 20: 1060-1067; discussion 1067-1068
32. Nishiyama R, Nakamura S, Suzuki S, Baba S. Platelet-activating factor in hepatic ischemia/reperfusion injury. The effects of a PAF antagonist combined with a prostaglandin I2 analogue. Transplantation 1993; 55: 1261-1265
33. Serizawa A, Nakamura S, Suzuki, Baba S, Nakano M. Involvement of platelet-activating factor in cytokine production and neutrophil activation after hepatic ischemia-reperfusion. Hepatology 1996; 23: 1656-1663
34. Suzuki S, Serizawa A, Sakaguchi T, Tsuchiya Y, Kojima Y, Okamoto K, Kurachi K, Konno, H, Fujise Y, Baba S, Nakamura S. The roles of platetet-activating factor and endothetin-1 in renal damage after total hepatic ischemia and reperfusion. Transplantation 2000; 69: 2267-2273
35. Aldemir M, Bosnak M, Al B, Buyukbayram H, Tacyildiz I. Effects of molsidomine and lexipafant in hepatic ischaemia-reperfusion injury. Injury 2004; 35: 232-237
36. Suzuki S, Toledo-Pereyra LH, Rodriguez FJ, Cejalvo D. Neutrophil infiltration as an important factor in liver ischemia and reperfusion injury. Modulating effects of FK506 and cyclosporine. Transplantation 1993; 55: 1265-1272
37. Yamakawa Y, Takano M, Patel M, Tien N, Takada T, Bulkley GB. Interaction of platelet activating factor, reactive oxygen species generated by xanthine oxidase, and leukocytes in the generation of hepatic injury after shock/resuscitation. Ann Surg 2000; 231: 387-398
38. Silomon M, Pizanis A, Larsen R, Rose S. Role of platelet-activating factor in hepatocellular Ca2+ alterations during hemorrhagic shock. J Surg Res 1997; 72: 101-106
39. Chao W, Olson MS. Platelet-activating factor: receptors and signal transduction. Biochem J 1993; 292 ( Pt 3): 617-629
40. Rose S, Pizanis A, Silomon M. Altered hepatocellular Ca2+ regulation during hemorrhagic shock and resuscitation. Hepatology 1997; 25: 379-384
41. Ohkawa H, Ohishi N, Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem 1979; 95: 351-358
42. Clavien PA, Harvey PR, Strasberg SM. Preservation and reperfusion injuries in liver allografts. An overview and synthesis of current studies. Transplantation 1992; 53: 957-978
43. Moreno P, Gijon MA, Fradera R, Fabregat J, Rafecas A, Biondo S, Figueras J, Sanchez-Crespo M, Jaurrieta E. Changes in peripheral blood levels of platelet-activating factor after orthotopic liver transplantation. Transplant Proc 1993; 25: 2642-2643
44. Hashikura Y, Kawasaki S, Matsunami H, Ikegami T, Makuuchi M. Intraoperative increment of platelet-activating factor in clinical liver transplantation. Clin Transplant 1994; 8: 27-29
45. Minor T, Yamaguchi T, Isselhard W. Treatment of preservation/reperfusion injury by platelet-activating factor antagonism in the rat liver graft. Transplant Proc 1995; 27: 522-523
46. Takada Y, Boudjema K, Jaeck D, Chenard MP, Wolf P, Cinqualbre J, Yamaoka Y. Platelet activating factor antagonist has a protective effect on preservation/ reperfusion injury of the graft in pig liver transplantation. Transplant Proc 1995; 27: 747-748
47. Spiegel HU, Oldhafer KJ, Lang H, Schuttler W, Bremer C, Pichlmayr R. Beneficial effect of the platelet-activating factor antagonist WEB 2170 on reperfusion injury after orthotopic liver transplantation. Transplant Proc 1995; 27: 2884-2885
48. Walcher F, Marzi I, Fischer R, Bauer M, Larsen R. Platelet-activating factor is involved in the regulation of pathological leukocyte adhesion after liver transplantation. J Surg Res 1996; 61: 244-249
49. Takada Y, Boudjema K, Jaeck D, Bel-Haouari M, Doghmi M, Chenard MP, Wolf P, Cinqualbre J. Effects of platelet-activating factor antagonist on preservation/reperfusion injury of the graft in porcine orthotopic liver transplantation. Transplantation 1995; 59: 10-16
50. Takada Y, Taniguchi H, Fukunaga K, Yuzawa K, Otsuka M, Todoroki T, Iijima T, Fukao K. Prolonged hepatic warm ischemia in non-heart-beating donors: protective effects of FK506 and a platelet activating factor antagonist in porcine liver transplantation. Surgery 1998; 123: 692-698
51. Mizoguchi Y, Ichikawa Y, Kioka K, Kobayashi K, Yamamoto S, Morisawa S. Possible involvement of platelet-activating factor in the induction of liver cell injury. Osaka City Med J 1990; 36: 121-128
52. Kleber G, Braillon A, Gaudin C, Champigneulle B, Cailmail S, Lebrec D. Hemodynamic effects of endotoxin and platelet activating factor in cirrhotic rats. Gastroenterology 1992; 103: 282-288
53. Huang L, Tan X, Crawford SE, Hsueh W. Platelet-activating factor and endotoxin induce tumour necrosis factor gene expression in rat intestine and liver. Immunology 1994; 83: 65-69
54. Gardner CR, Laskin JD, Laskin DL. Distinct biochemical responses of hepatic macrophages and endothelial cells to plate-let-activating factor during endotoxemia. J Leukoc Biol 1995; 57: 269-274
55. Caty MG, Guice KS, Oldham KT, Remick DG, Kunkel SI. Evidence for tumor necrosis factor-induced pulmonary microvascular injury after intestinal ischemia-reperfusion injury. Ann Surg 1990; 212: 694-700
56. Horie Y, Wolf R, Russell J, Shanley TP, Granger DN. Role of Kupffer cells in gut ischemia/reperfusion-induced hepatic microvascular dysfunction in mice. Hepatology 1997; 26: 1499-1505
57. Obi-Tabot ET, Hanrahan LM, Cachecho R, Beer ER, Hopkins SR, Chan JC, Shapiro JM, LaMorte WW. Changes in hepatocyte NADH fluorescence during prolonged hypoxia. J Surg Res 1993; 55: 575-580
58. Eppihimer MJ, Wolitzky B, Anderson DC, Labow MA, Granger DN. Heterogeneity of expression of E- and P-selectins in vivo. Circ Res 1996; 79: 560-569
59. Mustafa SB, Flickinger BD, Olson MS. Suppression of lipopolysaccharide-induced nitric oxide synthase expression by platelet-activating factor receptor antagonists in the rat liver and cultured rat Kupffer cells. Hepatology 1999; 30: 1206-1214
60. Ghosh S, Baltimore D. Activation in vitro of NF-kappa B by phosphorylation of its inhibitor I kappa B. Nature 1990; 344: 678-682
61. Pearson JM, Bailie MB, Fink GD, Roth RA. Neither platelet activating factor nor leukotrienes are critical mediators of liver injury after lipopolysaccharide administration. Toxicology 1997; 121:181-189
62. Murohisa G, Kobayashi Y, Kawasaki T, Nakamura S, Nakamura H. Involvement of platelet-activating factor in hepatic apoptosis and necrosis in chronic ethanol-fed rats given endotoxin. Liver 2002; 22: 394-403
63. Howard KM, Olson MS. The expression and localization of plasma platelet-activating factor acetylhydrolase in endotoxemic rats. J Biol Chem 2000; 275: 19891-19896
64. Zhang F. Protective effect of a platelet activating factor antagonist in experimental liver injury. Zhonghua Yixue Zazhi 1990; 70: 375-378, 26
65. Komatsu Y, Shiratori Y, Hikiba Y, Hashimoto N, Han K, Kawase T, Yoshida H, Okano K, Omata M. Role of platelet-activating factor in pathogenesis of galactosamine-lipopoly-saccharide-induced liver injury. Dig Dis Sci 1996; 41: 1030-1037
66. Bailie MB, Pearson JM, Fink GD, Roth RA. Platelet activating factor receptor blockade alone or in combination with leukotriene synthesis inhibition does not ameliorate alpha-naphthylisothiocyanate-induced hepatotoxicity. Toxicol Lett 1996; 84: 89-95
67. Grypioti AD, Theocharis SE, Papadimas GK, Demopoulos CA, Papadopoulou-Daifoti Z, Basayiannis AC, Mykoniatis MG. Platelet-activating factor (PAF) involvement in acetaminophen-induced liver toxicity and regeneration. Arch Toxicol 2005; 79: 466-474
68. Grypioti AD, Theocharis SE, Demopoulos CA, Papadopoulou-Daifoti Z, Basayiannis AC, Mykoniatis MG. Effect of platelet-activating factor (PAF) receptor antagonist (BN52021) on acetaminophen-induced acute liver injury and regeneration in rats. Liver Int 2006; 26: 97-105
69. Coker A, Coker I, Huseyinov A, Sokmen S, Karademir S. Is mannitol effective against platelet-activating factor (PAF)-induced liver damage in obstructive jaundice? Hepatogastroenterology 2001; 48: 1134-1137
70. Zhou W, Chao W, Levine BA, Olson MS. Role of platelet-activating factor in hepatic responses after bile duct ligation in rats. Am J Physiol 1992; 263: G587-592
71. Kerek M, Akyurek N, Sozuer EM, Arar M, Muhtaroglu S. Effects of recombinant platelet activating factor acetylhydrolase in obstructive jaundice. Hepatogastroenterology 2003; 50: 1097-1100
72. Mizuno S, Izumi T, Isaji S. Role of PAF in acute liver injury after extended hepatectomy: overexpression of PAF receptor mRNA in Kupffer cells. Dig Dis Sci 2001; 46: 1299-1304
73. Sakaguchi T, Nakamura S, Suzuki S, Oda T, Ichiyama A, Baba S, Okamoto T. Participation of platelet-activating factor in the lipopolysaccharide-induced liver injury in partially hepatectomized rats. Hepatology 1999; 30: 959-967
74. Rojkind M, Mourelle M. The liver as a bioecological system: modifications during regeneration and repair. In: Ninmi ME, ed. Collagen vol. 2. Boca Raton: CRC Press, 1988:137-160
75. Tsukamoto H, Matsuoka M, French SW. Experimental models of hepatic fibrosis: a review. Semin Liver Dis 1990; 10: 56-65
76. Caramelo C, Fernandez-Gallardo S, Santos JC, Inarrea P, Sanchez-Crespo M, Lopez-Novoa JM, Hernando L. Increased levels of platelet-activating factor in blood from patients with cirrhosis of the liver. Eur J Clin Invest 1987; 17: 7-11
77. Laffi G, Carloni V, Baldi E, Rossi ME, Azzari C, Gresele P, Marra F, Gentilini P. Impaired superoxide anion, platelet-activating factor, and leukotriene B4 synthesis by neutrophils in cirrhosis. Gastroenterology 1993; 105: 170-177
78. Rajkovic IA, Williams R. Abnormalities of neutrophil phagocytosis, intracellular killing and metabolic activity in alcoholic cirrhosis and hepatitis. Hepatology 1986; 6: 252-262
79. Stewart AG, Dubbin PN, Harris T, Dusting GJ. Platelet-activating factor may act as a second messenger in the release of icosanoids and superoxide anions from leukocytes and endothelial cells. Proc Natl Acad Sci USA 1990; 87: 3215-3219
80. Nathan N, Denziot Y. Platelet-activating factor and nonalcoholic cirrhotics. Gastroenterology 1993; 105: 1925-1926
81. Meade CJ, Birke F, Metcalfe S, Watson C, Jamieson N, Neild G. Serum PAF-acetylhydrolase in severe renal or hepatic disease in man: relationship to circulating levels of PAF and effects of nephrectomy or transplantation. J Lipid Mediat Cell Signal 1994; 9: 205-215
82. Kamisako T, Takeuchi K, Ito T, Tamaki S, Kosaka T, Adachi Y. Serum platelet-activating factor acetylhydrolase (PAF-AH) activity in patients with hyperbilirubinemic hepatobiliary disease. Hepatol Res 2003; 26: 23-27
83. Guerra R, Zhao B, Mooser V, Stafforini D, Johnston JM, Cohen JC. Determinants of plasma platelet-activating factor acetylhydrolase: heritability and relationship to plasma lipoproteins. J Lipid Res 1997; 38: 2281-2288
84. Villamediana LM, Sanz E, Fernandez-Gallardo S, Caramelo C, Sanchez Crespo M, Braquet P, Lopez-Novoa JM. Effects of the platelet-activating factor antagonist BN 52021 on the hemodynamics of rats with experimental cirrhosis of the liver. Life Sci 1986; 39: 201-205
85. Sanchez-Crespo M, Alonso F, Inarrea P, Alvarez V, Egido J. Vascular actions of synthetic PAF-acether (a synthetic platelet-activating factor) in the rat: evidence for a platelet independent mechanism. Immunopharmacology 1982; 4:173-185
86. Noda S, Masumi S, Moriyama M, Kannan Y, Ohta M, Sugano T, Yamate J. Population of hepatic macrophages and response of perfused liver to platelet-activating factor during production of thioacetamide-induced cirrhosis in rats. Hepatology 1996; 24: 412-418
87. Yang Y, Harvey SA, Gandhi CR. Kupffer cells are a major source of increased platelet activating factor in the CC14-induced cirrhotic rat liver. J Hepatol 2003; 39: 200-207
88. Yang Y, Nemoto EM, Harvey SA, Subbotin VM, Gandhi CR. Increased hepatic platelet activating factor (PAF) and PAF receptors in carbon tetrachloride induced liver cirrhosis. Gut 2004; 53: 877-883